The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Beta-blockers for hypertension
Open accessAbstract
BACKGROUND: Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line therapy for hypertension. However, the benefit of beta-blockers as first-line therapy for hypertension without compelling indications is controversial. This review is an update of a Cochrane Review initially published in 2007 and updated in 2012. OBJECTIVES: To assess the effects of beta-blockers on morbidity and mortality endpoints in adults with hypertension. SEARCH METHODS: The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to June 2016: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 6), MEDLINE (from 1946), Embase (from 1974), and ClinicalTrials.gov. We checked reference lists of relevant reviews, and reference lists of studies potentially eligible for inclusion in this review, and also searched the the World Health Organization International Clinical Trials Registry Platform on 06 July 2015. SELECTION CRITERIA: Randomised controlled trials (RCTs) of at least one year of duration, which assessed the effects of beta-blockers compared to placebo or other drugs, as first-line therapy for hypertension, on mortality and morbidity in adults. DATA COLLECTION AND ANALYSIS: We selected studies and extracted data in duplicate, resolving discrepancies by consensus. We expressed study results as risk ratios (RR) with 95% confidence intervals (CI) and conducted fixed-effect or random-effects meta-analyses, as appropriate. We also used GRADE to assess the certainty of the evidence. GRADE classifies the certainty of evidence as high (if we are confident that the true effect lies close to that of the estimate of effect), moderate (if the true effect is likely to be close to the estimate of effect), low (if the true effect may be substantially different from the estimate of effect), and very low (if we are very uncertain about the estimate of effect). MAIN RESULTS: Thirteen RCTs met inclusion criteria. They compared beta-blockers to placebo (4 RCTs, 23,613 participants), diuretics (5 RCTs, 18,241 participants), calcium-channel blockers (CCBs: 4 RCTs, 44,825 participants), and renin-angiotensin system (RAS) inhibitors (3 RCTs, 10,828 participants). These RCTs were conducted between the 1970s and 2000s and most of them had a high risk of bias resulting from limitations in study design, conduct, and data analysis. There were 40,245 participants taking beta-blockers, three-quarters of them taking atenolol. We found no outcome trials involving the newer vasodilating beta-blockers (e.g. nebivolol).There was no difference in all-cause mortality between beta-blockers and placebo (RR 0.99, 95% CI 0.88 to 1.11), diuretics or RAS inhibitors, but it was higher for beta-blockers compared to CCBs (RR 1.07, 95% CI 1.00 to 1.14). The evidence on mortality was of moderate-certainty for all comparisons.Total CVD was lower for beta-blockers compared to placebo (RR 0.88, 95% CI 0.79 to 0.97; low-certainty evidence), a reflection of the decrease in stroke (RR 0.80, 95% CI 0.66 to 0.96; low-certainty evidence) since there was no difference in coronary heart disease (CHD: RR 0.93, 95% CI 0.81 to 1.07; moderate-certainty evidence). The effect of beta-blockers on CVD was worse than that of CCBs (RR 1.18, 95% CI 1.08 to 1.29; moderate-certainty evidence), but was not different from that of diuretics (moderate-certainty) or RAS inhibitors (low-certainty). In addition, there was an increase in stroke in beta-blockers compared to CCBs (RR 1.24, 95% CI 1.11 to 1.40; moderate-certainty evidence) and RAS inhibitors (RR 1.30, 95% CI 1.11 to 1.53; moderate-certainty evidence). However, there was little or no difference in CHD between beta-blockers and diuretics (low-certainty evidence), CCBs (moderate-certainty evidence) or RAS inhibitors (low-certainty evidence). In the single trial involving participants aged 65 years and older, atenolol was associated with an increased CHD incidence compared to diuretics (RR 1.63, 95% CI 1.15 to 2.32). Participants taking beta-blockers were more likely to discontinue treatment due to adverse events than participants taking RAS inhibitors (RR 1.41, 95% CI 1.29 to 1.54; moderate-certainty evidence), but there was little or no difference with placebo, diuretics or CCBs (low-certainty evidence). AUTHORS' CONCLUSIONS: Most outcome RCTs on beta-blockers as initial therapy for hypertension have high risk of bias. Atenolol was the beta-blocker most used. Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest CVD reductions and little or no effects on mortality. These beta-blocke
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Self-citationHansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W. J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13800-7 · Cited by 1,872
Flather, M. D., Shibata, M. C., Coats, A. J. S., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., Cohen-Solal, A., Dumitrascu, D., Ferrari, R., Lechat, P., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi115 · Cited by 1,655
The CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Medical Research Council trial of treatment of hypertension in older adults: principal results.
Peart, S., Brennan, P. J., Broughton, P., Dollery, C. T., Hudson, M. F., Lever, A. F., Meade, T. W., Rose, G., & Pocock, S. (1992) · Cited by 1,360
Pepine, C. J., Handberg, E. M., Cooper-DeHoff, R. M., Marks, R. G., Kowey, P., Messerli, F. H., Mancia, G., Cangiano, J. L., Garcia-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,286
Materson, B. J., Reda, D. J., Cushman, W. C., Massie, B. M., Freis, E. D., Kochar, M. S., Hamburger, R. J., Fye, C., Lakshman, R., Gottdiener, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304013281303 · Cited by 1,199
Mancia, G., Fagard, R., Narkiewicz, K., Redán, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364ca4c · Cited by 1,190
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
Lindholm, L. H., Carlberg, B., & Samuelsson, O. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67573-3 · Cited by 999
Agodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Hansson, L., Hedner, T., Lund-Johansen, P., Kjeldsen, S. E., Lindholm, L. H., Syvertsen, J. O., Lanke, J., de Faire, U., Dahlöf, B., & Karlberg, B. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02526-5 · Cited by 905
Psaty, B. M. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540330061036 · Cited by 875
Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?
Konstantinou, D. M., Karvounis, H., & Giannakoulas, G. (2016) · Cardiology · doi:10.1159/000444078 · Cited by 870
Black, H. R. (2003) · JAMA · doi:10.1001/jama.289.16.2073 · Cited by 748
Randomised trial of treatment of hypertension in elderly patients in primary care.
Coope, J., & Warrender, T. S. (1986) · BMJ · doi:10.1136/bmj.293.6555.1145 · Cited by 725
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Messerli, F. H., Grossman, E., & Goldbourt, U. (1998) · JAMA · doi:10.1001/jama.279.23.1903 · Cited by 561
Greenburg, G. A. (1981) · PubMed · Cited by 545
Zanchetti, A., Bond, M. G., Hennig, M., Neiss, A., Mancia, G., Dal Palù, C., Hansson, L., Magnani, B., Rahn, K.-H., Reid, J. L., et al. (2002) · Circulation · doi:10.1161/01.cir.0000039288.86470.dd · Cited by 514
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
Staessen, J. A., Wang, J.-G., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00002 · Cited by 487
Beta-Blockers Versus Diuretics in Hypertensive Men: Main Results from the HAPPHY Trial
Wilhelmsen, L., Berglund, G., Elmfeldt, D., Fitzsimons, T., Holzgreve, H., Hosie, J., H??rnkvist, P.-E., Pennert, K., Tuomilehto, J., & Wedel, H. (1987) · Journal of Hypertension · doi:10.1097/00004872-198710000-00009 · Cited by 463
First-line drugs for hypertension
Wright, J. M., Musini, V. M., & Gill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001841.pub3 · Cited by 452
Wikstrand, J. (1988) · JAMA · doi:10.1001/jama.259.13.1976 · Cited by 408
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure
Gattis, W. A., O'Connor, C. M., Gallup, D. S., Hasselblad, V., & Gheorghiade, M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.12.040 · Cited by 374
British Hypertension Society guidelines for hypertension management 1999: summary
Ramsay, L. E., Williams, B., Johnston, G. D., MacGregor, G. A., Poston, L., Potter, J. F., Poulter, N. R., & Russell, G. (1999) · BMJ · doi:10.1136/bmj.319.7210.630 · Cited by 373
Verdecchia, P., Reboldi, G., Angeli, F., Gattobigio, R., Bentivoglio, M., Thijs, L., Staessen, J. A., & Porcellati, C. (2005) · Hypertension · doi:10.1161/01.hyp.0000174591.42889.a2 · Cited by 338
Potter, J. F., Robinson, T. G., Ford, G. A., Mistri, A., James, M., Chernova, J., & Jagger, C. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70263-1 · Cited by 331
(1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00054-x · Cited by 307
Zanchetti, A., Bond, M. G., Hennig, M., Neiss, A., Mancia, G., Palù, C. D., Hansson, L., Magnani, B., Rahn, K.-H., Reid, J., et al. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816070-00008 · Cited by 305
Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study
Dahlöf, B., Devereux, R. B., Julius, S., Kjeldsen, S. E., Beevers, G., de Faire, U., Fyhrquist, F., Hedner, T., Ibsen, H., Kristianson, K., et al. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.989 · Cited by 294
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290
CANZANELLO, V. J., & SHEPS, S. G. (1998) · Cardiology in Review · doi:10.1097/00045415-199809000-00009 · Cited by 277
Thomopoulos, C., Parati, G., & Zanchetti, A. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000447 · Cited by 275
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., McInnes, G. T., Mehlsen, J., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106000-00020 · Cited by 264
Kalinowski, L., Dobrucki, L. W., Szczepanska-Konkel, M., Jankowski, M., Martyniec, L., Angielski, S., & Malinski, T. (2003) · Circulation · doi:10.1161/01.cir.0000066912.58385.de · Cited by 239
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H., Mayosi, B. M., Maroney, R. T., Mbewu, A. D., Opie, L. H., & Volmink, J. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub2 · Cited by 237
Self-citationRe-examining the efficacy of -blockers for the treatment of hypertension: a meta-analysis
Khan, N. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060110 · Cited by 221
Broeders, M. A. W., Doevendans, P. A., Bekkers, B. C. A. M., Bronsaer, R., van Gorsel, E., Heemskerk, J. W. M., Egbrink, M. G. A. O., van Breda, E., Reneman, R. S., & van der Zee, R. (2000) · Circulation · doi:10.1161/01.cir.102.6.677 · Cited by 219
Interventions for deliberately altering blood pressure in acute stroke
Bath, P. M., & Krishnan, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000039.pub3 · Cited by 213
Mulcahy, R., & Hickey, N. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91654-2 · Cited by 203
ADVERSE REACTIONS TO BENDROFLUAZIDE AND PROPRANOLOL FOR THE TREATMENT OF MILD HYPERTENSION
(1981) · The Lancet · doi:10.1016/s0140-6736(81)90936-3 · Cited by 189
Sciarretta, S., Palano, F., Tocci, G., Baldini, R., & Volpe, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.427 · Cited by 185
First-line drugs for hypertension
Wright, J. M., & Musini, V. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001841.pub2 · Cited by 184
White, M., Yusuf, S., McKelvie, R. S., Pericak, D., Young, J. B., Latini, R., Pogue, J., Burns, R. J., Probstfield, J. L., Tsuyuki, R. T., et al. (2000) · Circulation · Cited by 183
Bradley, H. A., Wiysonge, C. S., Volmink, J. A., Mayosi, B. M., & Opie, L. H. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249685.58370.28 · Cited by 179
Self-citationOld antihypertensives and new diabetes
Opie, L. H., & Schall, R. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000133732.24501.9e · Cited by 168
Self-citationPhilipp, T., Anlauf, M., Distler, A., Holzgreve, H., Michaelis, J., & Wellek, S. (1997) · BMJ · doi:10.1136/bmj.315.7101.154 · Cited by 168
Wright, J. M., Lee, C., & Chambers, G. K. (1999) · Europe PMC (PubMed Central) · Cited by 167
BERGLUND, G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92624-6 · Cited by 166
Gupta, A. K., Nasothimiou, E. G., Chang, C. L., Sever, P. S., Dahlöf, B., & Poulter, N. R. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a8a42 · Cited by 165
Norris, K. C., Bourgoigne, J., Gassman, J., Hebert, L. A., Middleton, J. P., Phillips, R. A., Randall, O. S., Rostand, S. G., Sherer, S., Toto, R. D., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.08.004 · Cited by 163
Rouleau, J. L., Roecker, E. B., Tendera, M., Mohaçsi, P., Krum, H., Katus, H. A., Fowler, M. B., Coats, A. J. S., Castaigne, A., Scherhag, A. W., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.037 · Cited by 151
The vasodilatory beta-blockers
Pedersen, M. E. F., & Cockcroft, J. R. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0050-2 · Cited by 148
The Treatment of Mild Hypertension Study
(1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400070161023 · Cited by 147
Pepine, C. J., Handberg, E. M., Marks, R. G., Conlon, M., Cooper‐DeHoff, R. M., Volkers, P., & Zellig, P. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00423-9 · Cited by 146
Atenolol in Secondary Prevention after Stroke
Eriksson, S., Olofsson, B., & Wester, P. (1995) · Cerebrovascular Diseases · doi:10.1159/000107813 · Cited by 142
Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study.
Wikstrand, J., Warnold, I., Tuomilehto, J., Olsson, G., Barber, H. J., Eliasson, K., Elmfeldt, D., Jastrup, B., KARATZAS, N. B., & Leer, J. (1991) · Hypertension · doi:10.1161/01.hyp.17.4.579 · Cited by 136
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study
Bakris, G. L., Gaxiola, E., Messerli, F. H., Mancia, G., Erdine, S. E., Cooper‐DeHoff, R. M., & Pepine, C. J. (2004) · Hypertension · doi:10.1161/01.hyp.0000143851.23721.26 · Cited by 127
The Role of the New β-Blockers in Treating Cardiovascular Disease
Weber, M. A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.09.009 · Cited by 123
Blood Pressure Response Under Chronic Antihypertensive Drug Therapy
Protogerou, A., Blacher, J., Stergiou, G. S., Achimastos, A., & Safar, M. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.046 · Cited by 118
Angeli, F., Verdecchia, P., Reboldi, G., Gattobigio, R., Bentivoglio, M., Staessen, J. A., & Porcellati, C. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.002 · Cited by 112
β-Blockers: A Review of Their Pharmacological and Physiological Diversity in Hypertension
Ripley, T. L., & Saseen, J. J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013519591 · Cited by 109
Contemporary Use of β-Blockers: Clinical Relevance of Subclassification
Poirier, L., & Tobe, S. W. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.12.001 · Cited by 108
Wright, J. T., Kusek, J. W., Toto, R. D., Lee, J., Agodoa, L. Y. C., Kirk, K. A., Randall, O. S., & Glassock, R. J. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00081-5 · Cited by 105
Calcium channel blockers versus other classes of drugs for hypertension
Chen, N., Zhou, M., Yang, M., Guo, J., Zhu, C., Yang, J., Wang, Y., Yang, X., & He, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003654.pub4 · Cited by 99
Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension
Wong, G. W., Boyda, H. N., & Wright, J. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007451.pub2 · Cited by 96
Black, H. R., Elliott, W. J., Neaton, J. D., Grandits, G. A., Grambsch, P. M., Grimm, R. H., Hansson, L., Lacoucière, Y., Muller, J. E., Sleight, P., et al. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00013-0 · Cited by 96
Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension
Bangalore, S., Wild, D. M., Parkar, S., Kukin, M. L., & Messerli, F. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.057 · Cited by 94
Gottlieb, S. S., Fisher, M. L., KJEKSHUS, J. K., DEEDWANIA, P. C., Gullestad, L. L., Vítovec, J., & Wikstrand, J. (2002) · Circulation · doi:10.1161/hc1002.105180 · Cited by 91
Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis
Kuyper, L. M., & Khan, N. A. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.01.006 · Cited by 84
Bhavsar, N. A., Appel, L. J., Kusek, J. W., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.07.018 · Cited by 84
Olsson, G., Tuomilehto, J. O., Berglund, G., Elmfeldt, D., Warnold, I., Barber, H., Eliasson, K., Jastrup, B., KARATZAS, N. B., Leer, J., et al. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.2.151 · Cited by 81
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H., Volmink, J. A., Mayosi, B. M., Mbewu, A. D., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub4 · Cited by 78
Self-citationEvidence-based evaluation of calcium channel blockers for hypertension
Opie, L. H., & Schall, R. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01728-4 · Cited by 77
Self-citationPark, I. U., & Taylor, A. L. (2007) · The Annals of Family Medicine · doi:10.1370/afm.708 · Cited by 77
Berglund, G. L., ANDERSSON, O., & Widgren, B. R. (1986) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1986.tb02790.x · Cited by 74
Messerli, F. H. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01017-3 · Cited by 72
Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension
Wong, G. W., & Wright, J. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007452.pub2 · Cited by 69
β-Blockers in Hypertension: Studies and Meta-analyses Over the Years
Larochelle, P. M., Tobe, S. W., & Lacourcière, Y. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.012 · Cited by 66
Evidence-based medicine in hypertension: what type of evidence?
Zanchetti, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000170370.41387.1b · Cited by 64
Hjemdahl, P. (2005) · Heart · doi:10.1136/hrt.2004.057703 · Cited by 61
Otto Kamp, B., Metra, M., Bugatti, S., Bettari, L., Dei, A., Petrini, N., & Cas, L. D. (2009) · Drugs · doi:10.2165/11530710-000000000-00000 · Cited by 60
Ogihara, T., Matsuzaki, M., Matsuoka, H., Shimamoto, K., Shimada, K., Rakugi, H., Umemoto, S., Kamiya, A., Suzuki, N., Kumagai, H., et al. (2005) · Hypertension Research · doi:10.1291/hypres.28.331 · Cited by 60
Dietz, R., Dechend, R., Yu, C.-M., Bheda, M., Ford, J. H., PRESCOTT, M. F., & Keefe, D. L. (2008) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320308096411 · Cited by 51
Polónia, J. J., Barbosa, L., Silva, J. A., & Bertoquini, S. (2010) · Blood Pressure Monitoring · doi:10.1097/mbp.0b013e32833c8a64 · Cited by 50
Davis, E. M., Appel, L. J., Wang, X., Greene, T., Astor, B. C., Rahman, M., Toto, R. D., Lipkowitz, M. S., Pogue, V. A., & Wright, J. T. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.169367 · Cited by 46
STOP-Hypertension: Swedish Trial in Old Patients with Hypertension
Dahl??f, B., Hansson, L., Lindholm, L. H., et al. (1986) · Journal of Hypertension · doi:10.1097/00004872-198608000-00019 · Cited by 43
β-Blockers versus saluretics in hypertension
Wilhelmsen, L., Berglund, G. L., Elmfeldt, D., & Wedel, H. (1981) · Preventive Medicine · doi:10.1016/0091-7435(81)90004-9 · Cited by 36
Pucci, G., Ranalli, M. G., Battista, F., & Schillaci, G. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06467 · Cited by 36
Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease
Howlett, J. G. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.03.003 · Cited by 31
The Medical Research Council Hypertension Trial: The smoking patient
Dollery, C. T., & Brennan, P. J. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90650-3 · Cited by 30
Wong, G. W., Boyda, H. N., & Wright, J. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007450.pub2 · Cited by 29
Bakris, G. L., Iyengar, M. K., Lukas, M. A., Ordronneau, P., & Weber, M. A. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00341.x · Cited by 27
Gradman, A. H., Weir, M. R., Wright, M., Bush, C. A., & Keefe, D. L. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.11 · Cited by 27
Comparative Long Term Effects of Nebivolol and Carvedilol in Hypertensive Heart Failure Patients
Marazzi, G., Volterrani, M., Caminiti, G., Iaia, L., Massaro, R., Vitale, C., Sposato, B., Mercuro, G. G., & Rosano, G. M. C. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.05.001 · Cited by 24
Balamuthusamy, S., Molnár, J., Adigopula, S., & Arora, R. R. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fd87e · Cited by 22
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., & Po, W. (1987) · PubMed · Cited by 22
Gupta, A. K., Prieto‐Merino, D., Dahlöf, B., Sever, P., Poulter, N. R., & on behalf of the ASCOT Investigators (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03330.x · Cited by 21
Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study.
Tuomilehto, J., Wikstrand, J., Olsson, G., Elmfeldt, D., Warnold, I., Barber, H. J., Eliasson, K., Jastrup, B., KARATZAS, N. B., & Leer, J. (1989) · Hypertension · doi:10.1161/01.hyp.13.6.773 · Cited by 20
Nilsson, P. M. (2007) · Blood Pressure · doi:10.1080/08038020701561745 · Cited by 20
Phillips, R. A., Fonseca, V. A., Katholi, R. E., McGill, J. B., Messerli, F. H., Bell, D. S. H., Raskin, P., Wright, J. T., Iyengar, M. K., Anderson, K. M., et al. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00017.x · Cited by 20
The IPPPSH Collaborative Group, & B�hler, F. R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00549583 · Cited by 19
Beta-blockers and the treatment of hypertension: it is time to move on.
Wiysonge, C. S., Volmink, J. A., & Opie, L. H. (2007) · PubMed Central · Cited by 17
Self-citationZidek, W., Schrader, J., Lüders, S., Matthaei, S., Hasslacher, C., Hoyer, J. D., Bramlage, P., Sturm, C., & Paar, W. D. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-22 · Cited by 16
Thiazide Diuretics and β‐Blockers in the Treatment of Hypertension in Diabetes Mellitus
Sander, G. E., & Giles, T. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00454.x · Cited by 15
Fergus, I. V., Connell, K., & Ferdinand, K. C. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0592-x · Cited by 15
Zanchetti, A. (1996) · PubMed · Cited by 13
Recent Clinical Trials of Hypertension Management
Jennings, G. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00863 · Cited by 11
Barrios, V., Escobar, C., Tomás, J. P., Calderón, A., & Echarri, R. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.01.007 · Cited by 10
Evidence is needed that ß blockade alone reduces mortality in hypertension
Opie, L. H. (1997) · BMJ · doi:10.1136/bmj.315.7121.1544 · Cited by 10
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Lyle, P. A., Zhang, Z., & Edelman, J. M. (2007) · Blood Pressure · doi:10.1080/08037050701246386 · Cited by 10
Cited by
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Metadata
- Authors
- Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-01-20
- Volume
- 2017
- Issue
- 1
- Pages
- CD002003-CD002003
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1893697707
- Cited by
- 474
- References
- 156
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.